Belgian radiopharmaceutical firm Ion Beam Applications (IBA) of Louvain-la-Neuve has signed a licensing agreement for the worldwide marketing, distribution, and sales of Redectane from Wilex of Munich, Germany.
Redectane is a radiolabeled antibody detected by PET for the diagnosis of renal cell cancer. It currently is in phase III clinical trials.
IBA also will be responsible for manufacturing Redectane and will pay Wilex an initial fee, milestone payments, and other considerations as part of the agreement.
Related Reading
IBA finalizes acquisition of CIS bio, May 30, 2008
IBA opens U.K. production center, March 14, 2008
IBA posts mixed results for 2007, March 7, 2008
IBA inks French particle-beam therapy deal, February 7, 2008
IBA finalizes proton therapy deal, December 21, 2007
Copyright © 2008 AuntMinnie.com
